Olverembatinib, an investigational tyrosine kinase inhibitor (TKI), has shown promising antitumor activity and tolerability in a phase 1 study involving patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumor (GIST). As an orally active third-generation TKI, olverembatinib is being developed to address treatment resistance in GIST, especially in patients with advanced or metastatic disease.
The phase 1 study enrolled 20 patients with SDH-deficient GIST, predominantly with primary disease in the stomach, and most having received at least three prior lines of therapy. Patients were treated with 50 mg of olverembatinib every other day for up to 28 cycles. The clinical benefit rate was 93.8%, with treatment duration reaching up to 42 months. The promising results of the study highlight the drug’s potential in addressing the urgent treatment gap in SDH-deficient GIST, a rare subtype. The study results are considered encouraging and support further investigation of olverembatinib as a potential treatment for this challenging GIST subtype.
Reference: Tucker N. Olverembatinib Demonstrates Promising Outcomes in SDH-Deficient GIST. Targeted Oncology. Published June 8, 2023. Accessed April 5, 2024. https://www.targetedonc.com/view/olverembatinib-demonstrates-promising-outcomes-in-sdh-deficient-gist
